Myriad, Others Sue Gene by Gene Alleging Infringement of BRCA 1/2 Patents | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics and others have fired off another salvo against a company that began offering BRCA1 and BRCA2 testing following the US Supreme Court's decision last month invalidating Myriad's patent claims on isolated BRCA sequences.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.